Company Overview
Snapshot
Founded in July 2004 by Yossi Ben, Amorphical operates with 11–50 employees. The company has raised $28.3 million across six funding rounds, with ICU Group being one of the investors. In February 2026, Amorphical announced promising long-term Phase 2 clinical trial data for its novel mineral-based therapy for Crohn's disease, demonstrating a 62.5% sustained clinical remission rate at 48 weeks.
Business overview
Amorphical is a biotechnology company focused on developing and manufacturing natural-based medicines and dietary supplements. Its core technology centers on stabilizing and preserving amorphous calcium carbonate (ACC), a unique nanometric substance designed to improve calcium absorption and manage the body's acidity levels. The company's products aim to address various biomedical conditions, including bone deficiencies and severe diseases, primarily serving the Health Tech & Life Sciences sector, with applications in pharmaceuticals and biotechnology.
Strategic signal
In February 2026, Amorphical announced positive long-term data from its Phase 2 clinical trial for a non-immunosuppressive mineral-based therapy targeting moderate-to-severe Crohn's disease. This development is significant as it highlights the potential for long-term disease management without the risks associated with traditional immunosuppression, signaling strong progress towards regulatory submissions and expansion of its clinical program into the United States.
Log in to access full profile ›Company Intelligence Q&A
- What is the latest clinical trial update for Amorphical's Crohn's disease therapy?
- In February 2026, Amorphical announced promising long-term data from its Phase 2 trial for a novel, non-immunosuppressive mineral-based therapy for moderate-to-severe Crohn's disease. The data, presented at the ECCO Congress, showed a 62.5% sustained clinical remission rate at 48 weeks, supporting future regulatory submissions and expansion plans.
- What recent progress has Amorphical made in pancreatic cancer treatment?
- In November 2025, Amorphical enrolled its first patient in a Phase 2 clinical trial for a nano-amorphous mineral-based therapy targeting Stage IV pancreatic cancer. This trial, approved by the Helsinki Committee and the Israel Ministry of Health, aims to assess the therapy's impact on progression-free survival, overall survival, and quality of life by normalizing tumor acidity.
- What were the interim results of Amorphical's Crohn's disease clinical trial?
- In September 2025, Amorphical announced positive interim results from its ongoing open-label clinical trial for a nano-amorphous mineral-based therapy for moderate-to-severe Crohn's disease. The investigational therapy, which normalizes the acidic microenvironment in the gut, demonstrated significant clinical improvement and remission in patients, informing the company's future FDA regulatory strategy.
- Has there been a recent change in Amorphical's leadership?
- In September 2025, Amorphical appointed Eden Ben as its new CEO. This strategic move is intended to accelerate the company's development and regulatory milestones as it advances its pipeline of disease-modifying therapies and focuses on regulatory pathways in the U.S. and Europe.
- What was the outcome of Amorphical's clinical trial for COVID-19 treatment?
- In January 2022, Amorphical announced positive interim results from a Phase II clinical study of its COVID-19 treatment drug, AMOR-18. The study showed that hospitalized patients with moderate-to-severe COVID-19 who received AMOR-18 had a significantly reduced risk of ICU admission and mortality compared to the placebo group.